Barinthus Biotherapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Barinthus Biotherapeutics has a total shareholder equity of $187.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $214.5M and $27.5M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$142.09m |
| Equity | US$187.00m |
| Total liabilities | US$27.51m |
| Total assets | US$214.51m |
Recent financial health updates
Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation
Apr 05
We Think Vaccitech (NASDAQ:VACC) Can Afford To Drive Business Growth
Jul 07Recent updates
Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation
Apr 05We Think Vaccitech (NASDAQ:VACC) Can Afford To Drive Business Growth
Jul 07Vaccitech's (NASDAQ:VACC) Earnings Are Of Questionable Quality
Nov 17Vaccitech promotes Gemma Brown to CFO
Sep 20Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts
Aug 15Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 13Vaccitech GAAP EPS of $0.41, revenue of $17.06M
Aug 09Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%
May 19Vaccitech: Aiming For A Cure In Chronic Hepatitis B
Apr 03Vaccitech: The Next Big Vaccine Trade
Jun 27Vaccitech EPS misses by $0.69, beats on revenue
Jun 14Financial Position Analysis
Short Term Liabilities: BRNS's short term assets ($156.9M) exceed its short term liabilities ($12.6M).
Long Term Liabilities: BRNS's short term assets ($156.9M) exceed its long term liabilities ($14.9M).
Debt to Equity History and Analysis
Debt Level: BRNS is debt free.
Reducing Debt: BRNS had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BRNS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BRNS has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of 23.3% each year.